BGLC BioNexus Gene Lab Corp

  1. Stocks
  2. Basic Materials
  3. NASDAQ: BGLC

Price (delayed)

$2.14

Market cap

$5.17M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.49

Enterprise value

$4.18M

?
Relative Growth: Rel. Growth: 9
Relative Strength: Rel. Strength: 11
Relative Valuation: Rel. Valuation: 30
Relative Profitability: Rel. Profitability: 10
Highlights
The quick ratio has soared by 54% year-on-year but it has declined by 42% since the previous quarter
The net income has contracted by 37% YoY but it has grown by 2.7% from the previous quarter
BioNexus Gene Lab's gross profit has shrunk by 72% YoY and by 29% QoQ
The gross margin has dropped by 62% year-on-year
Sector: Basic Materials
Industry: Specialty Chemicals
Website: https://www.bionexusgenelab.com/
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of BGLC

BGLC stock price

How has the BioNexus Gene Lab stock price performed over time
Intraday
1.42%
1 week
-2.73%
1 month
6.2%
1 year
-26.59%
YTD
-45.82%
QTD
-0.03%

Financial performance

How have BioNexus Gene Lab's revenue and profit performed over time
Revenue
$5.29M
Gross profit
$765,356
Operating income
-$3.26M
Net income
-$2.9M
Gross margin
14.5%
Net margin
-54.9%
The net margin has dropped by 85% year-on-year and by 37% since the previous quarter
BioNexus Gene Lab's gross profit has shrunk by 72% YoY and by 29% QoQ
BioNexus Gene Lab's operating margin has shrunk by 68% YoY and by 35% QoQ
The gross margin has dropped by 62% year-on-year

Price vs fundamentals

How does BGLC's price correlate with its fundamentals

Growth

What is BioNexus Gene Lab's growth rate over time

Valuation

What is BioNexus Gene Lab stock price valuation
P/E
N/A
P/B
0.48
P/S
0.98
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.79
The EPS has contracted by 26% YoY but it has grown by 7% from the previous quarter
The P/B is 47% lower than the last 4 quarters average of 0.9
BioNexus Gene Lab's equity has decreased by 6% QoQ but it has increased by 4.1% YoY
The revenue has declined by 29% since the previous quarter and by 26% year-on-year
BGLC's price to sales (P/S) is 2% less than its last 4 quarters average of 1.0

Efficiency

How efficient is BioNexus Gene Lab business performance
The ROS has plunged by 84% YoY and by 37% from the previous quarter
The ROA has shrunk by 64% YoY
The return on equity has dropped by 55% year-on-year but it rose by 3.9% since the previous quarter
The return on invested capital has dropped by 52% year-on-year but it has increased by 3.4% since the previous quarter

Dividends

What is BGLC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BGLC.

Financial health

How did BioNexus Gene Lab financials performed over time
BioNexus Gene Lab's current ratio has soared by 56% YoY but it has decreased by 38% from the previous quarter
The quick ratio has soared by 54% year-on-year but it has declined by 42% since the previous quarter
The debt is 96% smaller than the equity
The debt has surged by 60% year-on-year and by 54% since the previous quarter
The company's debt to equity rose by 33% QoQ and by 33% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.